Cornick J, Martens J, Martens R, Crandell R, McConnell S, Kit S
Large Animal Medicine and Surgery, Texas Veterinary Medical Diagnostic Laboratory, Texas A&M University, College Station 77843-4475.
Can J Vet Res. 1990 Apr;54(2):260-6.
A drug induced equine herpesvirus-1 (EHV-1) mutant lacking thymidine kinase inducing activity was developed and evaluated as a vaccine. The safety and effectiveness of the vaccine to protect against experimentally induced EHV-1 respiratory disease were evaluated in weanling horses free of EHV-1 neutralizing antibody. The vaccine was safe when administered either intramuscularly or intravenously, and EHV-1 was not shed intranasally during the 12 days following administration. Intranasal challenge with virulent EHV-1 was used to evaluate vaccine efficacy. Following challenge, there was a significantly (p less than 0.05) greater increase in peak body temperatures and duration of nasal virus shedding in the nonvaccinates, and a significant (p less than 0.05) increase in serum neutralizing antibody titers in the vaccinates.
开发了一种缺乏胸苷激酶诱导活性的药物诱导马疱疹病毒1型（EHV-1）突变体，并将其作为疫苗进行评估。在没有EHV-1中和抗体的断奶马中评估了该疫苗预防实验性诱导的EHV-1呼吸道疾病的安全性和有效性。该疫苗通过肌肉注射或静脉注射给药时是安全的，并且在给药后的12天内没有通过鼻腔排出EHV-1。使用强毒EHV-1进行鼻腔攻毒以评估疫苗效力。攻毒后，未接种疫苗的马匹体温峰值和鼻腔病毒排出持续时间的增加显著（p小于0.05）更大，而接种疫苗的马匹血清中和抗体滴度显著（p小于0.05）增加。
